… our earlier-stage pipeline candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” … through intravitreal injections in the eye. About Axiomer and Trident ProQR is pioneering a next-generation RNA … yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called …
… into other forms of genetic blindness Validate and expand Axiomer ® : Further validate and expand ProQR's proprietary Axiomer ® RNA editing platform through first development … QR-1123, QR-421a, QR-411a, QR-504, the potential of our Axiomer ® editing platform, our plans and timing of …
… into clinical development and further advance our novel Axiomer ® RNA editing platform. With these events we look … or halt corneal degeneration in patients with FECD3. About Axiomer ProQR is pioneering a next-generation RNA technology called Axiomer ® , which could potentially yield a new class of …
… and key opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, … trial in 2018. Beyond that, we are excited about the Axiomer ® platform technology we announced at our R&D day. … the event, the Company also introduced its next-generation Axiomer ® RNA technology platform, which has the potential to …